Brokerages Set Ascendis Pharma A/S (NASDAQ:ASND) Price Target at $204.64

Ascendis Pharma A/S (NASDAQ:ASND) has received a consensus recommendation of “Moderate Buy” from the fourteen ratings firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and thirteen have assigned a buy recommendation to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $204.64.

Several equities research analysts recently commented on the company. JPMorgan Chase & Co. increased their price target on Ascendis Pharma A/S from $168.00 to $200.00 and gave the company an “overweight” rating in a report on Tuesday, March 18th. Cantor Fitzgerald upped their target price on Ascendis Pharma A/S from $170.00 to $200.00 and gave the company an “overweight” rating in a report on Tuesday, February 25th. Evercore ISI lifted their price target on Ascendis Pharma A/S from $220.00 to $260.00 and gave the stock an “outperform” rating in a report on Tuesday, February 18th. Morgan Stanley set a $180.00 price target on shares of Ascendis Pharma A/S in a research report on Tuesday, February 18th. Finally, The Goldman Sachs Group raised their price objective on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th.

Ascendis Pharma A/S Stock Down 2.1 %

Ascendis Pharma A/S stock opened at $154.68 on Tuesday. The company has a fifty day simple moving average of $144.16 and a 200-day simple moving average of $137.17. The firm has a market capitalization of $9.39 billion, a price-to-earnings ratio of -21.79 and a beta of 0.62. Ascendis Pharma A/S has a 52-week low of $111.09 and a 52-week high of $169.37.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.32) by $0.64. On average, research analysts anticipate that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Institutional Investors Weigh In On Ascendis Pharma A/S

Several institutional investors and hedge funds have recently modified their holdings of ASND. RA Capital Management L.P. increased its stake in Ascendis Pharma A/S by 4.1% during the fourth quarter. RA Capital Management L.P. now owns 10,112,744 shares of the biotechnology company’s stock worth $1,392,221,000 after purchasing an additional 402,316 shares during the period. Avoro Capital Advisors LLC grew its holdings in shares of Ascendis Pharma A/S by 2.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 5,103,055 shares of the biotechnology company’s stock valued at $702,538,000 after purchasing an additional 114,167 shares in the last quarter. Artisan Partners Limited Partnership increased its stake in Ascendis Pharma A/S by 0.9% during the 4th quarter. Artisan Partners Limited Partnership now owns 4,450,420 shares of the biotechnology company’s stock worth $612,689,000 after buying an additional 39,309 shares during the period. Janus Henderson Group PLC lifted its holdings in Ascendis Pharma A/S by 4.6% during the 4th quarter. Janus Henderson Group PLC now owns 4,380,382 shares of the biotechnology company’s stock worth $602,910,000 after buying an additional 193,688 shares in the last quarter. Finally, Capital International Investors boosted its position in Ascendis Pharma A/S by 35.7% in the 4th quarter. Capital International Investors now owns 2,863,249 shares of the biotechnology company’s stock valued at $394,183,000 after buying an additional 753,859 shares during the period.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.